Opiant Pharmaceuticals, Inc. (OPNT)

Mar 2, 2023 - OPNT was delisted (reason: acquired by Indivior)
20.65
0.00 (0.00%)
Last trade price
Market Cap 108.80M
Revenue (ttm) 22.34M
Net Income (ttm) -33.09M
Shares Out 5.27M
EPS (ttm) -6.57
PE Ratio n/a
Forward PE 26.74
Dividend n/a
Ex-Dividend Date n/a
Volume 492,256
Open 20.88
Previous Close 20.65
Day's Range 20.50 - 21.00
52-Week Range 7.34 - 29.25
Beta 0.83
Analysts Sell
Price Target 21.93 (+6.2%)
Earnings Date Mar 21, 2023

About OPNT

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorpo... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2005
Employees 37
Stock Exchange NASDAQ
Ticker Symbol OPNT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for OPNT stock is "Sell." The 12-month stock price forecast is $21.93, which is an increase of 6.20% from the latest price.

Price Target
$21.93
(6.20% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Indivior Completes Acquisition of Opiant Pharmaceuticals, Inc.

Combination Strengthens Indivior's Addiction Treatment and Science Portfolio RICHMOND, Va. , March 2, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV) ("Indivior" or the "Company") today announced that i...

2 weeks ago - PRNewsWire

Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC

SANTA MONICA, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced today that the Committee on Foreign Investment in the United States (CFIUS) approved the pr...

1 month ago - GlobeNewsWire

Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC

SANTA MONICA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced today the expiration of the waiting period under the United States (U.S.) Hart-Scott-Rodino...

1 month ago - GlobeNewsWire

Warren tells FTC she is "particularly concerned" about Amgen and Indivior deals

Sen. Elizabeth Warren, an outspoken critic of corporate consolidation, wrote to the U.S. Federal Trade Commission to express concern about two pending pharmaceutical deals.

Other symbols: AMGNHZNP
1 month ago - Reuters

Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose

SANTA MONICA, Calif., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review ...

2 months ago - GlobeNewsWire

Indivior Capital Markets Day Highlights Strategy for Shareholder Value Creation and Attractive Medium-Term Profitable Growth Outlook

- Peak Annual Net Revenue Potential for SUBLOCADE ®  Increased to > $1.5 Billion - Attractive and Scalable Business Outlined – Expects Strong Net Revenue Growth and Operating Margin Expansion Over the...

3 months ago - PRNewsWire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ELVT, OPNT, BNFT, ABMD

NEW YORK , Dec. 6, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches ...

Other symbols: ELVT
3 months ago - PRNewsWire

Opiant Pharmaceuticals Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid Overdose

SANTA MONICA, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced it has completed submission of its rolling New Drug Application (NDA) to ...

4 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Opiant Pharmaceuticals, Inc. Buyout

Wilmington, Delaware--(Newsfile Corp. - November 21, 2022) - Rigrodsky Law, P.A. is investigating Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT) regarding possible breaches of fiduciary duties...

4 months ago - Newsfile Corp

EQUITY ALERT: The M&A Class Action Firm Announces the Investigation of Opiant Pharmaceuticals, Inc. - OPNT

NEW YORK , Nov. 14, 2022 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm ra...

4 months ago - PRNewsWire

OPIANT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Opiant Pharmaceuticals, Inc. - OPNT

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Opiant Pharmac...

4 months ago - Business Wire

SHAREHOLDER ALERT: Weiss Law Investigates Opiant Pharmaceuticals, Inc.

NEW YORK , Nov. 14, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Opiant Pharmaceuticals, Inc. ("Opiant" ...

4 months ago - PRNewsWire

Why Is Opiant Pharma (OPNT) Stock Up 116% Today?

Opiant Pharmaceuticals (NASDAQ: OPNT) stock is rocketing higher on Monday following news that Indivior is acquiring the Narcan maker! Indivior is offering to acquire shares of OPNT stock for $28 each...

4 months ago - InvestorPlace

OPNT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Opiant Pharmaceuticals, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) to Indivior PLC is fair to Opiant sharehold...

4 months ago - Business Wire

Shareholder Alert: Ademi LLP investigates whether Opiant Pharmaceuticals Inc. has obtained a Fair Price in its transaction with Indivior

MILWAUKEE , Nov. 14, 2022 /PRNewswire/ -- Ademi LLP is investigating Opiant (NASDAQ: OPNT) for possible breaches of fiduciary duty and other violations of law in its transaction with Indivior.  Click ...

4 months ago - PRNewsWire

Opiant, maker of Narcan, to be acquired in $145 million deal

Shares of Opiant Pharmaceuticals Inc. OPNT, +1.06% soared 120.8% in premarket trading on Monday after the company, which is best known for selling the opioid overdose treatment Narcan, said it will be...

4 months ago - Market Watch

Opiant Pharmaceuticals Announces Third Quarter 2022 Financial Results

SANTA MONICA, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug ove...

4 months ago - GlobeNewsWire

Indivior PLC to Acquire Opiant Pharmaceuticals

SANTA MONICA, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) today announced that it has entered into a definitive merger agreement to be acquired by Indivior Inc...

4 months ago - GlobeNewsWire

Indivior To Acquire Opiant Pharmaceuticals

Acquisition Strengthens and Extends Indivior's Position as a Leader in Addiction Treatment Opiant Pipeline Anchored by OPNT003, an Opioid Overdose Treatment with Clinically Demonstrated Characteristic...

4 months ago - PRNewsWire

Opiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022

SANTA MONICA, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions...

5 months ago - GlobeNewsWire

Opiant Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OPNT002, Nasal Naltrexone, in Patients with Alcohol Use Disorder

SANTA MONICA, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (Opiant) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overd...

5 months ago - GlobeNewsWire

Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent with Claims Covering OPNT004 for the Treatment of Cannabinoid Hyperemesis Syndrome

SANTA MONICA, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (Opiant) (NASDAQ: OPNT) today announced that the United States Patent and Trademark Office (USPTO) has issued a Not...

7 months ago - GlobeNewsWire

MindMed Strengthens Board with Appointment of Two New Independent Directors

NEW YORK, Aug. 12, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain h...

Other symbols: MNMD
7 months ago - PRNewsWire

Opiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate Update

SANTA MONICA, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug ove...

7 months ago - GlobeNewsWire

Opiant Pharmaceuticals Announces Additional $2.1 Million Funding Under BARDA Contract for OPNT003, Nasal Nalmefene

SANTA MONICA, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced that the Biomedical Advanced Research and Development Authority (BARDA) h...

8 months ago - GlobeNewsWire